Selumetinib in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma

Summary

This phase II clinical trial is studying how well selumetinib works in treating patients with relapsed or refractory diffuse large B-cell lymphoma. Selumetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Timeline

Start

2010-12

Primary completion

2014-02

Completion

2014-05

Drugs

Indications